We have applied a proteolysis targeting chimera (PROTAC) technology to obtain a peptidomimetic molecule able to trigger the degradation of SARS-CoV-2 3-chymotrypsin-like protease (3CLPro). The PROTAC molecule was designed by conjugating a GC-376 based dipeptidyl 3CLPro ligand to a pomalidomide moiety through a piperazine−piperidine linker. NMR and crystallographic data complemented with enzymatic and cellular studies showed that (i) the dipeptidyl moiety of PROTAC binds to the active site of the dimeric state of SARS-CoV-2 3CLPro forming a reversible covalent bond with the sulfur atom of catalytic Cys145, (ii) the linker and the pomalidomide cereblon-ligand of PROTAC protrude from the protein, displaying a high degree of flexibility and no interactions with other regions of the protein, and (iii) PROTAC reduces the protein levels of SARS-CoV-2 3CLPro in cultured
Id prodotto:
137435
Handle IRIS:
11562/1118190
ultima modifica:
29 marzo 2024
Citazione bibliografica:
Grifagni, Deborah; Lenci, Elena; De Santis, Alessia; Orsetti, Andrea; Barracchia, CARLO GIORGIO; Tedesco, Filomena; Bellini Puglielli, Raffaele; Lucarelli, Francesca; Lauriola, Angela; Assfalg, Michael; Cantini, Francesca; Calderone, Vito; Guardavaccaro, Daniele; Trabocchi, Andrea; D’Onofrio, Mariapina; Simone Ciofi-Baffoni, And,
Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3‐Chymotrypsin-like Protease of SARS-CoV‐2«ACS MEDICINAL CHEMISTRY LETTERS»
, vol. 15
, n. 2
, 2024
, pp. 250-257